These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

113 related articles for article (PubMed ID: 9401941)

  • 21. Pharmacokinetics of (-)-(S)-bromofosfamide after intravenous and oral administration in mice.
    Kobylińska K; Kobylińska M; Sobik B
    Arzneimittelforschung; 2001; 51(7):596-9. PubMed ID: 11505792
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Preclinical pharmacokinetics of beta-L-dioxolane-cytidine, a novel anticancer agent, in rats.
    Moore LE; Boudinot FD; Chu CK
    Cancer Chemother Pharmacol; 1997; 39(6):532-6. PubMed ID: 9118465
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Analytical determination and pharmacokinetics of robenacoxib in the dog.
    Jung M; Lees P; Seewald W; King JN
    J Vet Pharmacol Ther; 2009 Feb; 32(1):41-8. PubMed ID: 19161454
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Phase I clinical and pharmacokinetic study of orally administered N4-palmitoyl-1-beta-D-arabinofuranosylcytosine.
    Ohno R; Kimura K; Ota K; Miura Y; Hoshino A; Hattori K; Hirano M; Ito M; Maekawa T; Nakamura T
    Med Oncol Tumor Pharmacother; 1987; 4(2):67-73. PubMed ID: 3669779
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Application of population pharmacokinetics to cladribine.
    Lindemalm S; Savic RM; Karlsson MO; Juliusson G; Liliemark J; Albertioni F
    BMC Pharmacol; 2005 Mar; 5():4. PubMed ID: 15757511
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Preclinical assessment of the absorption and disposition of the phosphatidylinositol 3-kinase/mammalian target of rapamycin inhibitor GDC-0980 and prediction of its pharmacokinetics and efficacy in human.
    Salphati L; Pang J; Plise EG; Lee LB; Olivero AG; Prior WW; Sampath D; Wong S; Zhang X
    Drug Metab Dispos; 2012 Sep; 40(9):1785-96. PubMed ID: 22696419
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Intracellular pharmacokinetics of N4-behenoyl-1-beta-D-arabinofuranosylcytosine.
    Higashigawa M; Hori H; Ochiai H; Ohkubo T; Kawasaki H; Nobori T; Kamiya H; Sakurai M
    Adv Exp Med Biol; 1989; 253B():341-8. PubMed ID: 2610121
    [No Abstract]   [Full Text] [Related]  

  • 28. The bioavailability and dose dependency of the deuterated anti-tumour agent 4,6-benzylidene-d1-D-glucose in mice and rats.
    Dunsaed CB; Dornish JM; Pettersen EO
    Cancer Chemother Pharmacol; 1995; 35(6):464-70. PubMed ID: 7882455
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [Pharmacokinetic studies of N4-behenoyl-1-beta-D-arabinofuranosylcytosine (BH-AC) by 30-minute infusion with acute nonlymphocytic leukemia--the possibility of administration for outpatients].
    Hirosawa S
    Gan To Kagaku Ryoho; 1988 Jun; 15(6):1991-3. PubMed ID: 3164182
    [No Abstract]   [Full Text] [Related]  

  • 30. Treatment of murine L1210 lymphoid leukemia and melanoma B16 with lipophilic cytosine arabinoside prodrugs incorporated into unilamellar liposomes.
    Rubas W; Supersaxo A; Weder HG; Hartmann HR; Hengartner H; Schott H; Schwendener R
    Int J Cancer; 1986 Jan; 37(1):149-54. PubMed ID: 3941019
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Clinical pharmacology of 1-beta-D-arabinofuranosylcytosine-5'-stearylphosphate, an orally administered long-acting derivative of low-dose 1-beta-D-arabinofuranosylcytosine.
    Ueda T; Kamiya K; Urasaki Y; Wataya S; Kawai Y; Tsutani H; Sugiyama M; Nakamura T
    Cancer Res; 1994 Jan; 54(1):109-13. PubMed ID: 8261429
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Close correlation of 1-beta-D-arabinofuranosylcytosine 5'-triphosphate, an intracellular active metabolite, to the therapeutic efficacy of N(4)-behenoyl-1-beta-D-arabinofuranosylcytosine therapy for acute myelogenous leukemia.
    Yamauchi T; Kawai Y; Goto N; Kishi S; Imamura S; Yoshida A; Urasaki Y; Fukushima T; Iwasaki H; Tsutani H; Masada M; Ueda T
    Jpn J Cancer Res; 2001 Sep; 92(9):975-82. PubMed ID: 11572766
    [TBL] [Abstract][Full Text] [Related]  

  • 33. High performance liquid chromatographic analysis and preclinical pharmacokinetics of the heteroarotinoid antitumor agent, SHetA2.
    Zhang Y; Hua Y; Benbrook DM; Covey JM; Dai G; Liu Z; Chan KK
    Cancer Chemother Pharmacol; 2006 Nov; 58(5):561-9. PubMed ID: 16534614
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Pharmacokinetics of CPX-351 (cytarabine/daunorubicin HCl) liposome injection in the mouse.
    Bayne WF; Mayer LD; Swenson CE
    J Pharm Sci; 2009 Jul; 98(7):2540-8. PubMed ID: 19009594
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Gender-related pharmacokinetics and absolute bioavailability of diosbulbin B in rats determined by ultra-performance liquid chromatography-tandem mass spectrometry.
    Yang B; Wang X; Liu W; Zhang Q; Chen K; Ma Y; Wang C; Wang Z
    J Ethnopharmacol; 2013 Oct; 149(3):810-5. PubMed ID: 23954278
    [TBL] [Abstract][Full Text] [Related]  

  • 36. cis-Amminedichloro(2-methylpyridine) platinum(II) (AMD473), a novel sterically hindered platinum complex: in vivo activity, toxicology, and pharmacokinetics in mice.
    Raynaud FI; Boxall FE; Goddard PM; Valenti M; Jones M; Murrer BA; Abrams M; Kelland LR
    Clin Cancer Res; 1997 Nov; 3(11):2063-74. PubMed ID: 9815598
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Pharmacokinetics of Ara-CMP-Stearate (YNK01): phase I study of the oral Ara-C derivative.
    Schleyer E; Braess J; Ramsauer B; Unterhalt M; Kaufmann C; Wilde S; Schüssler M; Hiddemann W
    Leukemia; 1995 Jun; 9(6):1085-90. PubMed ID: 7596174
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Therapy of refractory/relapsed acute leukemia with cytosine arabinoside plus tetrahydrouridine (an inhibitor of cytidine deaminase)--a pilot study.
    Kreis W; Budman DR; Chan K; Allen SL; Schulman P; Lichtman S; Weiselberg L; Schuster M; Freeman J; Akerman S
    Leukemia; 1991 Nov; 5(11):991-8. PubMed ID: 1961042
    [TBL] [Abstract][Full Text] [Related]  

  • 39. In vivo distribution of 14C-labeled N4-behenoyl-1-beta-D-arabinofuranosylcytosine in mice.
    Toyoshima S; Fukuma M; Seto Y; Fujita H; Fukushima K; Tomioka H; Sakurai T; Sugimoto Y; Yagi T; Hoshino T; Sowa T
    Gan; 1981 Feb; 72(1):19-29. PubMed ID: 7274645
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Suramin as a chemosensitizer: oral pharmacokinetics in rats.
    Ogden A; Wientjes MG; Au JL
    Pharm Res; 2004 Nov; 21(11):2058-63. PubMed ID: 15587928
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.